pr-inside.com
Print

ABLYNX PROMOTED TO THE BELGIAN MID-CAP INDEX



2013-02-20 18:08:46 -


GHENT, Belgium, 20 February 2013 - Ablynx [Euronext Brussels: ABLX], a
biopharmaceutical company engaged in the discovery and development of
Nanobodies®, a novel class of therapeutic proteins based on single-domain
antibody fragments for a range of serious human diseases, today announced its
promotion to the Belgian Mid-Cap Index (Bel Mid Index or BELMID). Ablynx will be
included in the BELMID Index as of the 18(th) of March 2013.

The entry of Ablynx to the BELMID Index is a result of performance of the Ablynx
shares and is based on Ablynx's market capitalisation, free float and liquidity
in the period up to end of January 2013.


About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies(®), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 25 programmes in the pipeline and five Nanobodies at clinical
development stage. Ablynx has ongoing research collaborations and significant
partnerships with major pharmaceutical companies including Boehringer Ingelheim,
Merck Serono, Novartis and Merck & Co. The Company is headquartered in Ghent,
Belgium. More information can be found on www.ablynx.com.



For more information, please contact

Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX


M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t:   +44 207 920 2330
e:  ablynx@mcomgroup.com


press release in pdf format:
hugin.info/137912/R/1679682/548575.pdf



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Ablynx via Thomson Reuters ONE
[HUG#1679682]


Press Information:




Contact Person:


Phone:
email: e-mail




Disclaimer: © 2014 Thomson Reuters. The press releases or report contained herein is protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Thomson Reuters's, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.